Novo Nordisk's 52% Plunge: Is the Company Fumbling Its Leadership in the $150 Billion Weight Loss Market?
Nothing attracts competition like the opportunity for profits, and the weight loss drug market has become arguably the healthcare industry's hottest opportunity in recent memory. Novo Nordisk(NYSE: NVO) has enjoyed tremendous success with semaglutide, the proprietary drug in Ozempic and Wegovy.
However, competition is picking up with multiple next-generation drugs working through clinical testing.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
The market is worried about Novo Nordisk's grip on the weight loss market, evidenced by the stock plummeting over 52% from its mid-2024 high. Does Wall Street have it wrong, or is Novo Nordisk fumbling a generational growth opportunity?
Here is what you need to know.
The competition is heating up in the weight loss market
Research by Morgan Stanley estimates the weight loss market could grow from roughly $15 billion last year to approximately $150 billion by 2035. GLP-1 agonists are currently the drug of choice, which slow digestion and suppress the patient's appetite.
Novo Nordisk has an estimated 62% market share of the GLP-1 agonist market, with archrival Eli Lilly accounting for another 35%. Investors are looking ahead to next-generation drugs that could deliver better results with fewer side effects. That includes next-generation injectable treatments and pill-form drugs, which most patients probably prefer to a needle.
Novo Nordisk hopes to receive regulatory approval to market and sell its semaglutide weight loss drug Wegovy in pill form by year-end. Meanwhile, CagriSema, currently in phase 3 clinical trials, is the company's next-generation injectable drug. However, it has struggled to stand out from existing treatments in late-stage clinical tests.
Will these products maintain Novo Nordisk's weight loss leadership? It's hard to tell.
Eli Lilly's orforglipron has performed well in its initial phase 3 clinical testing. It's an oral pill and the first small-molecule GLP-1 agonist to pass a phase 3 study, which is potentially significant because small-molecule drugs are generally easier and cheaper to manufacture.
There are dozens of weight loss drugs in various development stages across the industry, so competition is coming.
Don't assume Novo Nordisk will lose its crown
Novo Nordisk's competitors were never going to stand and watch it dominate a $150 billion opportunity, but that doesn't necessarily mean Novo Nordisk will lose its crown.
Investors have grown afraid of competition, but the drug development process is extremely daunting. Far more drugs fail the regulatory process than reach the market. Pfizer, a fellow pharmaceutical heavyweight, had hopes to crack the weight loss market with its oral GLP-1 agonist danuglipron, but it abandoned development in April after it potentially caused a liver injury in a patient during clinical tests.
Several factors ultimately decide which treatments patients choose, including efficacy, price, and side effects. In other words, it's probably unfair to conclude what will happen until these new and upcoming drugs have been on the market for a while.
Novo Nordisk and Eli Lilly may continue to dominate market share, though they could trade blows, and the balance between them could shift.
The stock's slide mitigates a lot of risk
Still, investors and the market have assumed that Novo Nordisk will ultimately cede market share. Analysts have dramatically lowered their long-term earnings growth estimates for Novo Nordisk. But here is the good news -- the stock already reflects these lower expectations.
Novo Nordisk trades at a price-to-earnings (P/E) ratio of 20 today, down from roughly 50 over the summer. Even if the market is correct and Novo Nordisk grows by an average of 14% annually, today's valuation is still attractive for that growth. That wouldn't be the case at 50 times earnings, but its current PEG ratio of 1.4 is an attractive price tag for an industry leader in a high-growth industry like this.
There are always risks in the pharmaceutical business. Novo Nordisk could suffer an unexpected setback or drug failure, or a competitive drug could be so good that it tilts the balance of the weight loss market away from Novo Nordisk.
Still, Novo Nordisk is a proven industry leader and probably deserves some more faith until proven otherwise. Barring a worst-case scenario, the stock has a good shot to work out well for long-term investors from these discounted prices.
Should you invest $1,000 in Novo Nordisk right now?
Before you buy stock in Novo Nordisk, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider whenNetflixmade this list on December 17, 2004... if you invested $1,000 at the time of our recommendation,you'd have $639,271!* Or when Nvidiamade this list on April 15, 2005... if you invested $1,000 at the time of our recommendation,you'd have $804,688!*
Now, it's worth notingStock Advisor's total average return is957% — a market-crushing outperformance compared to167%for the S&P 500. Don't miss out on the latest top 10 list, available when you joinStock Advisor.
See the 10 stocks »
*Stock Advisor returns as of May 19, 2025
Justin Pope has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
10 minutes ago
- Globe and Mail
3 American Growth Giants to Invest in for the Long Haul
Many of the best growth stocks in the world are based out of the U.S. This is the land of both opportunity and innovation. Warren Buffett has always been bullish on betting on the U.S. because he's a big believer in American business. If you want to follow suit and invest in some of the country's best growth stocks, there are three excellent names that I don't think you can go wrong with in the long term: Nvidia (NASDAQ: NVDA), Eli Lilly (NYSE: LLY), and Palo Alto Networks (NASDAQ: PANW). These three stocks are growth beasts, and they still have plenty more room to run over the long haul. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » Nvidia Chipmaking giant Nvidia, one of the most valuable companies in the world, is based out of Santa Clara, California. Its history goes back more than 30 years to 1993. One of the remarkable features of this business is that it has had only one CEO, Jensen Huang, who co-founded the company. That's a good sign of continuity and underscores just how stable the business has been over the years. In its most recent fiscal year, which ended on Jan. 26, the company reported $130 billion in revenue, which was more than double the $61 billion it posted a year earlier, as demand for its artificial intelligence (AI) chips remains robust. But what impresses me most is just how incredible its profit margins are: typically well north of 50%. Nvidia is based in the U.S. but it isn't immune to the effects of tariffs or trade wars, especially with China being a key market for its operations. But with such high profit margins, it's in much better shape than other companies to be able to absorb higher costs and headwinds related to economic uncertainty. That's why this can be a no-brainer growth stock to buy right now. Eli Lilly Indianapolis-based Eli Lilly is another great American growth stock to buy and hold. Founded in 1876, its history goes back nearly 150 years. And for decades, the business has been developing vital medicines for people to help improve their lives. One of the more exciting ones of late has been related to weight loss and obesity. Its GLP-1 drug Tirzepatide resulted in two highly successful products for Eli Lilly: Zepbound for weight loss and Mounjaro for diabetes. Together, those drugs generated more than $6 billion in sales through the first three months of 2025, representing nearly half of the top line, which rose by 45%. What's exciting here is that there is still so much potential for these drugs to generate more growth since they are still in their early stages. Plus, there are studies suggesting that GLP-1 drugs could even help with substance abuse by curbing addictions, which means there may be even more indications that tirzepatide is approved for in the future. And yet, Eli Lilly's business goes beyond just GLP-1, which is why this can be a fantastic growth stock to buy and hold. Tariffs could increase its costs, and a global trade war would affect its bottom line. But it, too, has some solid profit margins at around 22%. Palo Alto Networks Rounding out this list of impressive American growth stocks is Palo Alto Networks, a cybersecurity company founded 20 years ago. Like Nvidia, its headquarters is also in Santa Clara. And as all things related to AI grow, businesses and consumers alike will need to ramp up their cybersecurity. Since the need for cybersecurity is ongoing, the company benefits from a large chunk of its top line being from recurring revenue. Its subscription and support segment generated $1.8 billion in sales for the quarter ended April 30, which accounted for 80% of its top line (product revenue made up the rest). And while overall revenue rose by 15%, the annualized recurring revenue for the company's next-generation security rose by 34%. Palo Alto's profit margin of 15% is light when compared to the other stocks on this list, but that's still a solid percentage of revenue flowing through to its bottom line. And it's a big improvement from just a few years ago when the business was still in the red. Results for the company's fiscal 2025 third quarter (ended April 30) included revenue of $2.3 billion, up from $2 billion a year ago. GAAP net income was unchanged at $300 million for the quarter. Palo Alto has come a long way in recent years, and while it may look like an expensive stock, trading at more than 100 times its trailing earnings, that valuation should improve as it continues to scale up and its margins get even better. While Palo Alto may experience a slowdown in business if a trade war affects spending, its top line relies heavily on software and support services, making it less vulnerable to tariffs than other stocks. For long-term investors, this can be another solid stock to own given the huge opportunities in cybersecurity in the years ahead. Should you invest $1,000 in Nvidia right now? Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $651,761!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $826,263!* Now, it's worth noting Stock Advisor 's total average return is978% — a market-crushing outperformance compared to170%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of May 19, 2025
Globe and Mail
40 minutes ago
- Globe and Mail
Beyond the Hype: 2 Top Under-the-Radar AI Stocks to Watch in 2025
As artificial intelligence (AI) continues to transform industries, a few blue-chip stocks like Amazon (AMZN), Nvidia (NVDA), and Microsoft (MSFT) dominate headlines. However, this does not always imply that they are the only viable investments in AI. Under-the-radar stocks, on the other hand, may be reasonably priced and have room for more expansion. Here are some lesser-known companies gaining traction in the AI space. #1: Arista Networks Valued at $116.5 billion, Arista Networks (ANET) is a leading provider of high-performance networking solutions for large data centers, cloud computing environments, campuses, and enterprise networks. The stock has experienced short-term volatility this year, primarily due to concerns about customer concentration, falling 21.4% year to date. Nonetheless, Arista's long-term outlook remains positive, with Wall Street expecting the stock to rise as much as 50% from current levels. As AI workloads require more from network infrastructures, Arista has strategically positioned itself to meet these demands. Ethernet-based solutions from the company are gaining popularity over traditional InfiniBand systems due to their scalability and cost-effectiveness. Arista began 2025 with a strong performance in Q1, reporting record-breaking revenues of $2 billion, up 27.6% annually. Adjusted net income increased 30% to $0.65 per share, exceeding consensus expectations. Management highlighted that adjusted gross margin went slightly above expectations to 64.1%, supported by an efficient supply chain and a healthy mix of enterprise and cloud customers. In the Q1 earnings call, CEO Jayshree Ullal emphasized Arista's growing presence in AI and cloud networking. The company expressed confidence in meeting its $750 million AI front-end goal by 2025. Arista aims to be the leading scale-out network provider for Nvidia's evolving GPU (graphics processing units) and AI accelerator roadmap, with its Etherlink portfolio serving as a key differentiator in large AI cluster performance. The company ended the quarter with a total of $8.15 billion in cash, equivalents, and marketable securities. During the quarter, it spent $787.1 million on stock repurchases, its largest repurchase to date. It also announced a new $1.5 billion stock buyback authorization, boosting investor confidence in long-term growth. Even with ongoing macroeconomic volatility and tariff uncertainty, Arista remains optimistic. With growing opportunities in AI, cloud, and campus infrastructure, the company is confident of meeting and possibly exceeding the $10 billion revenue milestone ahead of schedule. Analysts who cover the stock remain optimistic about the company's future. Revenue and earnings are expected to rise by 19.6% and 12.4%, respectively, in 2025, with further double-digit growth in 2026. Arista stock appears to be expensive, trading at 31 times forward earnings, but this reflects investors' confidence in the company's long-term growth prospects. The company's strategic investments in AI networking, combined with its strong financial health, position it well to capitalize on new opportunities. On Wall Street, Arista stock holds an overall rating of ' Moderate Buy.' Of the 22 analysts covering the stock, 14 rate it as a "Strong Buy," two as a "Moderate Buy," and six recommend a 'Hold.' The stock's average target price of $111.68 suggests a potential upside of 27% from current levels, while the highest price estimate of $130 indicates a possible 50% rally over the next 12 months. #2: Vertiv Holdings Valued at $41.6 billion, Vertiv Holdings (VRT) specializes in designing, manufacturing, and servicing infrastructure technologies for data centers, communication networks, and commercial and industrial environments. Its product portfolio comprises power management systems, thermal management solutions, and IT management tools. Vertiv's stock is down 4.4% year-to-date. The surge in AI applications has increased the demand for high-density data centers. Vertiv is capitalizing on this trend by offering advanced cooling and power solutions specifically designed for AI workloads. The company posted a strong first quarter of 2025. Vertiv reported a 49% increase in earnings to $0.64 per share, exceeding expectations by $0.04, thanks to 25% organic net sales growth and a record book-to-bill ratio of 1.4x. In the Q1 earnings call, CEO Giordano Albertazzi stated that the company's visibility into the data center market, particularly AI infrastructure, gives management confidence not only for 2025, but also for the long term. Vertiv ended the quarter with nearly $1.5 billion in cash and cash equivalents and $265 million in adjusted free cash flow. Management stated that Vertiv has spent the last two years developing a resilient, geopolitically diverse supply chain. The company operates with strong local capacity in the U.S. and Mexico and has begun relocating production away from high-tariff regions. Vertiv raised its 2025 sales growth guidance to 18%, citing strong demand signals from AI and hyperscale customers. The midpoint EPS guidance of $3.55 remains unchanged, implying 25% year-over-year growth, despite the company expecting a $50 million headwind from U.S.-China tariff impacts in the second quarter. Analysts predict revenue growth in the same range, with earnings rising by 25% by 2025. Currently, Vertiv stock is trading at 30 times forward earnings. While the global tariff environment is complex, the company's proactive supply chain strategy and solid financial position it for continued success in 2025 and beyond. On Wall Street, Vertiv stock holds an overall rating of ' Strong Buy.' Of the 19 analysts covering the stock, 15 rate it as a "Strong Buy," one as a "Moderate Buy," and three recommend a 'Hold.' The stock's average target price of $119.50 suggests a potential upside of 9.1% from current levels, while the highest price estimate of $150 indicates a possible 37% rally over the next 12 months.
CTV News
41 minutes ago
- CTV News
MLB pitcher hires security after online death threats, some aimed at 5-year-old daughter
Houston Astros starting pitcher Lance McCullers Jr. reacts after a throw during the first inning of a baseball game against the Texas Rangers, Friday, May 16, 2025, in Arlington, Texas. (AP Photo/LM Otero) HOUSTON — Soon after Lance McCullers Jr.'s family received online death threats following a tough start by the Houston Astros' pitcher, his 5-year-old daughter, Ava, overheard wife Kara talking on the phone about it. What followed was a painful conversation between McCullers and his little girl. 'She asked me when I came home: 'Daddy like what is threats? Who wants to hurt us? Who wants to hurt me?'' McCullers told The Associated Press on Wednesday. 'So, those conversations are tough to deal with.' McCullers is one of two MLB pitchers whose families have received online death threats this month as internet abuse of players and their families is on the rise. Boston reliever Liam Hendriks took to social media soon after the incident with McCullers to call out people who were threatening his wife's life and directing 'vile' comments at him. The Astros contacted MLB security and the Houston Police Department following the threats to McCullers. An police spokesperson said Thursday that it remains an ongoing investigation. McCullers, who has two young daughters, took immediate action after the threats and hired 24-hour security for his family. 'You have to at that point,' he said. Abuse increasing with rise in sports gambling Players from around the league agree that online abuse has gotten progressively worse in recent years. Milwaukee's Christian Yelich, a 13-year MLB veteran and the 2018 NL MVP, said receiving online abuse is 'a nightly thing' for most players. 'I think over the last few years it's definitely increased,' he said. 'It's increased to the point that you're just: 'All right, here we go.' It doesn't even really register on your radar anymore. I don't know if that's a good or a bad thing. You're just so used to that on a day-to-day, night-to-night basis. It's not just me. It's everybody in here, based on performance.' And many players believe it's directly linked to the rise in legalized sports betting. 'You get a lot of DMs or stuff like that about you ruining someone's bet or something ridiculous like that,' veteran Red Sox reliever Justin Wilson said. 'I guess they should make better bets.' Hendriks has had enough Hendriks, a 36-year-old reliever who previously battled non-Hodgkin lymphoma, said on Instagram that he and his wife received death threats after a loss to the Mets. He added that people left comments saying that they wished he would have died from cancer among other abusive comments. He later discussed the issue and his decision to speak out about it. 'Enough is enough,' he said. 'Like at some point, everyone just like sucking up and dealing with it isn't accomplishing anything. And we pass along to security. We pass along to whoever we need to, but nothing ends up happening. And it happens again the next night. And so, at some point, someone has to make a stand. And it's one of those things where the more eyes we get on it, the more voices we get talking about it. Hopefully it can push it in the right direction.' What teams are doing Both the Astros and the Red Sox are working with MLB security to take action against social media users who direct threats toward players and their families. Red Sox spokesperson Abby Murphy added that they've taken steps in recent years to make sure player' families are safe during games. That includes security staff and Boston police stationed in the family section at home and dedicated security in the traveling party to monitor the family section on the road. Murphy said identifying those who make anonymous threats online is difficult, but: 'both the Red Sox and MLB have cyber programs and analysts dedicated to identifying and removing these accounts.' The Astros have uniformed police officers stationed in the family section, a practice that was implemented well before the threats to McCullers and his family. Abandoning social media For some players, online abuse has gotten so bad that they've abandoned social media. Detroit All-Star outfielder Riley Greene is one of them, saying he got off because he received so many messages from people blaming him for failed bets. 'I deleted it,' he said of Instagram. 'I'm off it. It sucks, but it's the world we live in, and we can't do anything about it. People would DM me and say nasty things, tell me how bad of a player I am, and say nasty stuff that we don't want to hear.' Criticism is part of the game, threats are not The 31-year-old McCullers, who returned this year after missing two full seasons with injuries, said dealing with this has been the worst thing that's happened in his career. He understands the passion of fans and knows that being criticized for a poor performance is part of the game. But he believes there's a 'moral line' that fans shouldn't cross. 'People should want us to succeed,' he said. 'We want to succeed, but it shouldn't come at a cost to our families, the kids in our life, having to feel like they're not safe where they live or where they sit at games.' Houston manager Joe Espada was livid when he learned about the threats to McCullers and his family and was visibly upset when he addressed what happened with reporters. Espada added that the team has mental health professionals available to the players to talk about the toll such abuse takes on them and any other issues they may be dealing with. 'We are aware that when we step on the field, fans expect and we expect the best out of ourselves,' Espada said this week. 'But when we are trying to do our best and things don't go our way while we're trying to give you everything we got and now you're threatening our families and kids — now I do have a big issue with that, right? I just did not like it.' Kansas City's Salvador Perez, a 14-year MLB veteran, hasn't experienced online abuse but was appalled by what happened to McCullers. If something like that happened to him he said it would change the way he interacts with fans. 'Now some fans, real fans, they're gonna pay for that, too,' he said. 'Because if I was him, I wouldn't take a picture or sign anything for noboby because of that one day.' McCullers wouldn't go that far but admitted it has changed his mindset. 'It does make you kind of shell up a little bit,' he said. 'It does make you kind of not want to go places. I guess that's just probably the human reaction to it.' Finding a solution While most players have dealt with some level of online abuse in their careers, no one has a good idea of how to stop it. 'I'm thankful I'm not in a position where I have to find a solution to this,' Tigers' pitcher Tyler Holton said. 'But as a person who is involved in this, I wish this wasn't a topic of conversation.' White Sox outfielder Mike Tauchman is disheartened at how bad player abuse has gotten. While it's mostly online, he added that he's had teammates that have had racist and homophobic things yelled at them during games. 'Outside of just simply not having social media I really don't see that getting better before it just continues to get worse,' he said. 'I mean, I think it's kind of the way things are now. Like, people just feel like they have the right to say whatever they want to whoever they want and it's behind a keyboard and there's really no repercussions, right?' ___ Kristie Rieken, The Associated Press AP Baseball Writer Mike Fitzpatrick and AP Sports Writers Jimmy Golen, Kyle Hightower, Larry Lage and Steve Megargee contributed to this report.
